Skip to main content
. Author manuscript; available in PMC: 2008 Jun 20.
Published in final edited form as: Oncogene. 2007 Apr 2;26(42):6133–6140. doi: 10.1038/sj.onc.1210436

Figure 6. Antagonism of mir-29b protects cells from apoptosis.

Figure 6

Panel a: Western blot of total protein isolated from non-malignant H69 cells and malignant KMCH cells transfected with control RNA, pre-mir-29b, or the mir-29 antagonist oligonucleotide, LNA (50nM each). Panel b. Apoptotic morphology measured as in Figure 5 on H69 and KMCH cells transfected as above. Note that H69 cells are sensitive to TRAIL killing, as noted in previous studies, while KMCH cells are relatively resistant unless mir-29b is transfected. Mean ± SEM, **p<0.0001 compared to vehicle treated control; # p<0.01 compared to TRAIL-treated mir-29; ## p<0.0001 compared to TRAIL-treated mir-29. Panel c: Caspase 3/7-like activity (DEVDase) on cells transfected as above. Caspase activity parallels the apoptosis counts using morphology. Mean ± SEM, *p<0.01 compared to vehicle treated control; **p<0.0001 compared to vehicle treated control; ## p<0.0001 compared to TRAIL-treated mir-29.